EligibleTrials

DESTINY-PANTUMOUR04

Recruiting · NCT07124000 · Observational (researchers observe without assigning treatment) · Lead sponsor: AstraZeneca

View the official record on ClinicalTrials.gov →
Colorectal cancerLung cancerMelanomaPancreatic CancerProstate Cancer

Interventions studied

Trastuzumab deruxtecan

What this trial is about

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Who can take part

Age range
18 Years to 130 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

36 locations listed across 13 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.